We recently described the upregulation of HLA-E in ovarian and cervical cancers. Instead of interacting with natural killer cells, HLA-E appeared to inhibit intratumoral cytotoxic T lymphocytes (CTL) via the receptor CD94/NKG2A. Strikingly, the survival benefit of intraepithelial infiltrating CTL was lost in those cancers with high HLA-E expression.</p
BACKGROUND: Human Leucocyte Antigen- E (HLA-E) has been reported as both a positive and negative pro...
International audienceWe previously demonstrated that HLA-E/β2m overexpression by tumor cells in col...
International audienceWe previously demonstrated that HLA-E/β2m overexpression by tumor cells in col...
We recently described the upregulation of HLA-E in ovarian and cervical cancers. Instead of interact...
We recently described the upregulation of HLA-E in ovarian and cervical cancers. Instead of interact...
We recently described the upregulation of HLA-E in ovarian and cervical cancers. Instead of interact...
HLA-E is a nonclassical HLA class I molecule, which differs from classical HLA molecules by its nonp...
HLA-E is a nonclassical HLA class I molecule, which differs from classical HLA molecules by its nonp...
HLA-E is a nonclassical HLA class I molecule, which differs from classical HLA molecules by its nonp...
HLA-E is a nonclassical HLA class I molecule, which differs from classical HLA molecules by its nonp...
HLA-E is a nonclassical HLA class I molecule, which differs from classical HLA molecules by its nonp...
Immunotherapy treatments with anti-PD-1 boost recovery in less than 30% of treated cancer patients, ...
Immunotherapy treatments with anti-PD-1 boost recovery in less than 30% of treated cancer patients, ...
Background: Human Leucocyte Antigen-E (HLA-E) has been reported as both a positive and negative prog...
BACKGROUND: Human Leucocyte Antigen- E (HLA-E) has been reported as both a positive and negative pro...
BACKGROUND: Human Leucocyte Antigen- E (HLA-E) has been reported as both a positive and negative pro...
International audienceWe previously demonstrated that HLA-E/β2m overexpression by tumor cells in col...
International audienceWe previously demonstrated that HLA-E/β2m overexpression by tumor cells in col...
We recently described the upregulation of HLA-E in ovarian and cervical cancers. Instead of interact...
We recently described the upregulation of HLA-E in ovarian and cervical cancers. Instead of interact...
We recently described the upregulation of HLA-E in ovarian and cervical cancers. Instead of interact...
HLA-E is a nonclassical HLA class I molecule, which differs from classical HLA molecules by its nonp...
HLA-E is a nonclassical HLA class I molecule, which differs from classical HLA molecules by its nonp...
HLA-E is a nonclassical HLA class I molecule, which differs from classical HLA molecules by its nonp...
HLA-E is a nonclassical HLA class I molecule, which differs from classical HLA molecules by its nonp...
HLA-E is a nonclassical HLA class I molecule, which differs from classical HLA molecules by its nonp...
Immunotherapy treatments with anti-PD-1 boost recovery in less than 30% of treated cancer patients, ...
Immunotherapy treatments with anti-PD-1 boost recovery in less than 30% of treated cancer patients, ...
Background: Human Leucocyte Antigen-E (HLA-E) has been reported as both a positive and negative prog...
BACKGROUND: Human Leucocyte Antigen- E (HLA-E) has been reported as both a positive and negative pro...
BACKGROUND: Human Leucocyte Antigen- E (HLA-E) has been reported as both a positive and negative pro...
International audienceWe previously demonstrated that HLA-E/β2m overexpression by tumor cells in col...
International audienceWe previously demonstrated that HLA-E/β2m overexpression by tumor cells in col...
DOI
Add to ORKG